GBE possesses many constituents, and is mainly composed of flavonoids such as quercetin andrutin, and terpenoids such as bilobalide and ginkgolides A, B and C. 2) In German pharmaceutical analysis, the quality of GBE has been standardized ascontaining 22-27% flavonoid glycosides and 6% terpenoids. 3) In recent clinical and experimental experiments, GBE has been reported to be effective against ischemic brain injury, 4, 5) cerebral (or cerebrovascular) insufficiency, 6) cognitive speed, 7) dementia and Alzheimer's disease, 8) peripheral vascular disease such as arterial occlusive disease 9) and aging damages. 10) Actually, these effects have been recognized clinically using many double-blind studies with GBE versus placebo. [11] [12] [13] The mechanisms for thebeneficial effects of GBE are considered to be due to the improvements of (a) haemodynamic disorders 14, 15) ; (b) PAF-associated abnormalities [16] [17] [18] ; (c) cell damages induced by free radicals [16] [17] [18] ; and (d) decrease in ATP level during anoxia. 19) GBE modulates cytochrome (CYP) P450. GBE induced markedly the activity of CYP2B, CYP3A1 and CYP3A2 in the rat liver. 20, 21) These results suggest that GBE attenuates the therapeutic potency of nicardipine due to the induction of the CYP3A2 level. It is still unknown whether GBE can pass through the blood-brain barrier. The endothelial productions (i.e., NO) induced by GBE application might pass through the blood-brain barrier and then would cause the vasodilation in cerebral arteries. The concentrations used in our studies are relatively higher, because the concentrations in in vitro experiments are generally higher than actual clinical serum concentrations. The pharmacological activities of GBE mainly was attributed to ginkgolides ( Fig. 1) .
Accumulating evidence suggested that ginkgolide B(GB) shows the strongest pharmacological activity among the ginkgolides. Now, GB is being developed for treating cerebrovascular accident, but no information is available on systemic and comprehensive pharmacokinetics of GB. In this study, we report for the first time a thorough characterization of the pharmacokinetics of GB and providing large data sets that can be used to predict biological events related to pharmacokinetic behavior of GB through determining the concentrations in biological samples after intravenous administration of GB emulsion to rats.
MATERIALS AND METHODS

Chemicals and Reagents
Ginkgolide B was supplied by National Institute for the Control of Pharmaceutical and Biological Produces (Beijing, China). 23-OH betulic acid (internal standard) was obtained from Chemistry Institute of China Pharmaceutical University. GB emulsion was presented by Beijing 303 Hospital. All other reagents were commercially available. Water was purified using Milli-Q Labo (Millipore, U.S.A.). Sprague-Dawley rats, weighing 180-220 g, were supplied by Experimental Animal Center of China Pharmaceutical University. The rats were fasted but allowed free access to water 12 h prior to experiment. Ginkgo B (GB) is an extract from the leaves of Ginkgo biloba, used in the treatment of dementia, cerebral insufficiency or related cognitive decline. In this paper, the main features of the pharmacokinetics of GB emulsion in rats were reviewed and the binding rate of GB to rat plasma and human plasma protein were investigated meanwhile. The concentrations of GB in plasma, tissue, and excretion of rats after i.v. administration of GB were measured using HPLC-ESI-MS. The metabolite was qualitated by LC-MS/MS. Intravenously administered GB was eliminated in a biphasic manner with a prominent initial phase (half-life of 0. raphy was performed using a Shimadzu LC-10AD HPLC system equipped with an autosampler (SIL-HTc). The HPLC was coupled to a Shimadzu LCMS-2010A quadrupole mass spectrometer with an ESI interface. Data acquisition and processing were accomplished using Shimadzu LCMS solution Software for the LCMS-2010A system.
LC-MS Apparatus and Conditions Liquid chromatog-
Chromatographic separation was achieved on a Shim-pack stainless-steel column (C 18 , 5 mm, 150 mmϫ2.0 mm I.D., Shimadzu) at 40°C. Mobile phase A consisted of 1 mmol/l ammonium acetate and 0.04‰ triethylamine in water and mobile phase B was methanol. All mobile phases were filtered through a 0.25 mm membrane and degassed under reduced pressure. Linear gradient elution was employed within a 10 min running time and its sequence was as follows: beginning with 40% of mobile phase A and 60% of mobile phase B, which was held for 2.5 min, then the mobile phase A to B ratio was gradually change to 10 : 90 at 3.5 min and held up to 5.0 min, followed by returning to the initial composition. Analyses were conducted at a flow rate of 0.2 ml/min. The ESI source was used in negative ionization mode. The [MϪH] Ϫ ions of GB (m/z 423.15) and of 23-OH betulic acid (m/z 471.00) were selected as ions for SIM detection. The quantification was performed using peak areas. The MS operating conditions were optimized and the optimized parameters were as follows: drying gas 1.5 l/min, CDL temperature 250°C, block temperature 200°C, probe voltage ϩ4.5 kV.
Plasma Sample Preparation QC samples, calibration standards, and clinical plasma samples, were extracted employing a liquid-liquid extraction technique. To each tube containing 20 ml plasma, 20 ml of the 10 mg/ml solution of internal standard and 1.0 ml of diethyl ether were added, and the mixture was then vortexed for 2 min. The samples were then centrifuged for 10 min at 40000ϫg. The organic layer was removed and evaporated under a stream of nitrogen at 40°C. The residue was re-dissolved in 300 ml methanol. An aliquot of 2 ml was injected into the LC-MS system.
Single Dosing Study Design A total of 30 (15 males, 15 females) SD rats, weighing 200Ϯ20 g, were fed on standard commercial rat pellets and were allowed access to fresh drinking water for 4 d before experiment. The study protocols were in accordance with the instructions for the care and use provided by the institution. Then, 30 rats were randomly assigned to three groups of 5 male and 5 female rats in each, weighed and injected with GB in 4, 12 and 36 mg/kg through tail vein, respectively. Fifty microliters blood was obtained by puncture of retro-orbital sinus under ether anesthesia at 3, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 480 min with a heparinized capillary tube. Blood samples was then centrifuged at 3000 rpm for 20 min, 20 ml plasma sample was used for determining the concentration of GB in plasma. Sodium heparin was used as anticoagulant. The obtained plasma was pooled and stored at Ϫ70°C until assay. The animals were sacrificed at the end of the sampling period by injection with an overdose (60 mg/kg) of sodium pentobarbitone.
Multiple Dosing Study Design Doses of 12 mg of GB per kg were administered to 10 (5 males, 5 females) SD rats, every 8 h for 8 d. Blood samples were obtained on day 8 at 0 min (predose) and at 3, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 480 min after administration. Additional samples were obtained at 0 min (predose) on days 5, 6 and 7. All blood samples were collected using heparin containing tubes. Within 30 min of collection, blood samples were centrifuged for 20 min at approximately 4°C and at approximately 4000ϫg. The plasma was separated, transferred into 2 tubes, stored at Ϫ70°C until assay.
Tissue Distribution Studies GB was administered to eighteen male and female SD rats(weighing 250Ϯ50 g,) in the tail vein at a dose of 12 mg/kg and then randomly divided into three groups. After 10 min, 1 h and 6 h, blood samples were collected into heparinised tubes by puncture of retro-orbital sinus, respectively. Then, the rats were sacrificed, and their tissues were excised and dried with filter paper. Tissues were excised as follows: heart, liver, spleen, lung, kidney, stomach, duodenum, brain, fat (around testis or ovary), skin, skeletal muscle (femoral region), ovary and testis. One-tenth gram of each tissue was precisely weighed, places into 1 ml of physiological saline, homogenized, and centrifuged at 10000ϫg for 5 min. Supernatant was processed and determined as plasma described above.
Excretion in Bile after Single Administration Five male and female rats were anaesthetized with sodium pentobaritone. A polyethylenetube (PE-19; Clay Adams, U.S.A.) was then inserted into the common bile duct. After confirming the flow of bile, GB was injected to the rats in the tail vein at a dose of 12 mg/kg. The rats were housed in restraining cages and allowed to free access to food and water. Their bile was individually collected at 0-2, 2-4, 4-6, 6-8, 8-12 h after administration. The amount of bile was measured and 20 ml supernatant was processed and determined as plasma described above. 2 ml extracted sample was directly injected onto the HPLC column.
Plasma Protein Binding Determination The plasma protein binding of GB was determined by equilibrium dialysis.
12) Dialysis was carried out in a 25 ml vial with dialysis membrane (molecular weight cutoff, 10000) at 4°C. Twenty vials filled with 10 ml phosphate buffer (0.133 mol/l phosphate, 0.9% sodium chloride, pH 7.4), were divided into four groups, and 0.05, 0.2, 1.0 and 5.0 mg/l GB were added into the vials, respectively. Twenty dialysis membranes with two ends tied, each 5 cm-long, containing 0.5 ml blank plasma, were placed into the twenty-five vials. In a preliminary experiment, the optimum equilibrium time for GB binding to plasma protein was determined to be 90 h. Therefore, blank plasma was dialyzed for 90 h against phosphate buffer spiked with GB at 4°C. At equilibrium, plasma and buffer samples were collected, extracted and determined as plasma samples described above. The plasma protein binding of GB was calculated according to the equation: the binding rate of GB to plasma protein (%)ϭ(C in ϪC out )/C in ϫ100%, where C in is the concentration of GB inside the membrane, and Cout the concentration of GB outside the membrane.
Metabolite Profiling-Sample Preparation Urines and biles were pooled by route of administration and time period. To 20 ml rat urine and bile were added 1.0 ml methanol in a 2.0 ml centrifuged tube. The tubes were mixed 5 min and centrifuged for 5 min at 10000ϫg. Two microliters supernatant was injected into the LC-MS system.
Preparation of Calibration Curves and Determination of Intra-and Inter-assay Precision
A stock solution containing 1.0 mg/ml GB was prepared in HPLC-grade methanol, stored at 4°C and prepared monthly. The required standard solutions were obtained by serial dilutions of the concentrated standard solution in methanol. Calibration curves were prepared daily by spiking duplicate drug-free rat plasma, tissue or excretion with GB, followed by extraction as described above. Quality control (QC) samples were prepared independently from the calibration curves by spiking drug-free plasma with known amounts of GB. Four different levels, corresponding to low (5 ng/ml GB in plasma), medium (20 ng/ml and 200 ng/ml in plasma) and high (2.0 mg/ml in plasma) concentrations of the QC samples were prepared. The intra-assay (within-day) precision and accuracy were assessed by analyzing six sets of quality control samples in a batch. The inter-assay reproducibility was assessed by analyzing six sets of quality control samples on three different batches.
Pharmacokinetic and Statistical Analysis Pharmacokinetic parameters were calculated for each individual experiment. The curves were imitated using BAPP program of pharmacokinetic (Key Lab of Drug Metabolism & Pharmacokinetics, China Pharmaceutical University, Nanjing, China). Pharmacokinetic parameters of GB were calculated and presented as mean values. The concentration of GB in tissues and excretion of GB were expressed as xϮs.
RESULTS
Chromatography
The ultrabase C18 column and the simple mobile phase used were found to be appropriate for the analysis of ginkgolide B. Under the assay conditions described, retention times for ginkgolide B and the internal standard were found 4.9 and 8.9 min, respectively. In Fig. 2 , the chromatograms obtained for drug-free rat samples (plasma and liver) and post-dose rat samples obtained after intravenous administration of ginkgolide B. Results obtained showed that no endogenous interferences were observed in the blanks. Chromatograms of heart, spleen, lung, kidney, brain, muscle, stomach, duodenum, rectum, skin, fat and genitalia were similar to those of liver samples.
The concentrations of GB in plasma, tissue, and excretion samples were calculated from relative calibration lines. The calibration lines were computed using peak-area to the concentrations of GB spiked with plasma, tissue, or excretion. We decided to keep the calibration range from 5 to 1000 ng/ml and dilute the samples which concentration beyond 1000 ng/ml using corresponding blank sample. The analytical method has a limit of quantification (LOQ) for GB, defined as the lowest concentration measured with acceptable precision and accuracy, was 1 ng/ml and was linear between 5 and 1000 ng/ml. The coefficient of determination for the calibration curve (peak-area) was more than 0.999. The mean absolute percentage recoveries of GB were more than 90%, from spiked plasma, tissue, and excretion samples determined at four different concentrations of 5, 20, 200, and 1000 ng/ml (nϭ5). At four different concentrations of 5, 20, 200, and 1000 ng/ml, the within-run relative standard derivations (RSD) were 5.2%, 5.7%, 2.4% and 1.2% (nϭ6), repectively. Between 3 days, they were 10.6%, 9.7%, 5.0% and 2.1% (nϭ6), respectively. These data showed the method to be precise, reproducible, and suitable for the analysis of biosamples.
Pharmacokinetic Parameters of Single Dosing Figure  3 shows the decay in the concentration of GB in rat plasma as a function of time after i.v. administration of 4, 12, and 36 mg/kg. The concentration-time curves were adequately described by a two-compartment model. Pharmacokinetic parameters from a two-compartment model analysis of plasma samples for intravenous GB are summarized in Table  1 . Under these experimental conditions, the elimination halflife of GB ranged from 60.3 to 95.6 min, its total body clearance from 0.05 to 0.07 l · kg Ϫ1 · min Ϫ1 and AUC 0-8 from Table 1 . Pharmacokinetic Parameters of GB in Rats after i.v. Administration of GB at Single Doses of GB .
Pharmacokinetic Parameters of Multiple Dosing
The minimum serum concentrations from days 5 to 7 were analyzed (see Table 2 ) and similar concentrations were found when 12 mg/kg of GB were administrated, therefore we can say that steady state was achieved before 5th day. Pharmacokinetic parameters from a two-compartment model analysis of plasma samples are summarized in Table 3 . The mean degree of accumulation of GB was consistent with the t 1/2 and dose frequency and was not considered relevant. Table 4 shows the concentrations of GB in rat tissues after i.v. administration of GB at a dose of 12 mg/kg. The experimental results demonstrated that after i.v. administration GB, greatest concentrations of GB in all tissues except brain and fat reached a peak at 10 min. The concentration levels in many tissues such as heart, liver, kidney, stomach and duodenum were approximately 1.5-5 times greater than in plasma for all the time, and the highest concentration was observed in liver. As the time increased, the concentrations of GB rapidly decreased from each tissue by several folds (by 20-50 times), in which the drug distribution rate decreased gradually.
Distribution of GB in Rats
Excretion in Urine, Feces and Bile The cumulative excretion ratios of GB in the urine and feces after i.v. administration of GB at a dose of 12 mg/kg are shown in Table 5 . The cumulative urinary, fecal excretion of GB was 45.41% and 25.95%, respectively, of the total dose by 48 h after dosing. Excretion of GB into bile was a little fraction, and almost completed within 4 h after administration, with cumulative excretion ratio of 0.47% of the dosed GB. The majority of GB was excreted within 24 h after administration.
Plasma Protein Binding of GB Using equilibrium dialysis method, the binding rates of GB to rat and human plasma protein were found to be 21.09-26.70% and 17.99-21.49%, respectively, varying with the concentration of GB from 0.05 to 5.0 mg/l ( Table 6 ). The binding rate to rat plasma was little higher than to human plasma, but the difference was negligible (pϾ0.05).
Metabolite Profiles Urine: After intravenous doses, many new components were scanned by LC-MS/MS. The mass spectrum of the major new components had molecular ions (m/z 441 t R ϭ3.0 min, m/z 457 t R ϭ3.6 min), of which accounted for more than 15% (see Fig. 4) .
Bile: In the 0-4 and 4-12 h biles of i.v. dosed rats, the components (m/z 441 t R ϭ3.0 min, m/z 457 t R ϭ2.7 min) were detected by LC-MS/MS. The mass chromatograms of the new component were shown in Fig. 5 . The metabolism study of GB is being undertaken in our Lab and the experimental results will be reported afterwards. 4 Vol. 30, No. 1 
DISCUSSION
The proposed analytical method provided a rapid, sensitive and specific assay for GB determination in biological samples. A simple liquid-liquid extraction procedure and a short run time limited the total anaylysis time, and this is important for large sample batches. It was shown that this method is suitable for the analysis of GB in pre-clinical and clinical studies.
The pharmacokinetic studies have shown that, after i.v. administration to rats, elimination of GB dose range from 4 to 36 mg/kg. The linear and dose-independent pharmacokinetics of GB indicate that the processed leading to elimination of GB are not saturated. When comparing the AUC, C max between single dosing and multiple dosing, no significant difference was found. Furthermore, GB was well tolerated when administered at doses of 12 mg/kg in this group of rats. No serious adverse events were observed GB in plasma was thought to be eliminated mainly by uptake into liver. After i.v. administration of GB to rats, the highest concentration of GB appear in the liver all the time. Sixty minutes after i.v. administration of GB to rats, the concentration of GB in brain was 148.9Ϯ45.6 ng/ml, we can conclude that GB can quickly transport the blood brain barrier, which conform to the treatment of cerebrovascular pharmacodynamic action of GB.
The dosed GB was mainly excreted into urine in unchanged form, and about 2.5% of the dosed GB into feces. This indicated that more than 50% of GB was finally eliminated in metabolite form. The metabolism study of GB is being undertaken in our lab and the experimental results will be reported afterwards.
The protein binding ratio of GB in the plasma is about 20%, in other words, the unbound fraction is around 80%. That is the reason why the urinary excretion pathway is the main elimination route.
In summary, pharmacokinetic research results show that GB has a great potential clinic value. The distributional properties of GB in the present rats study are beneficial to its cerebrovascular pharmacodynamic action. 
